Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q4 FY25 results · Jan–Mar 2025
Torrent Pharmaceuticals reported revenue from operations of ₹2,959.00 crore (up 7.8% from Q4 FY24) and net profit of ₹498.00 crore (up 10.9% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,959.00 | 2,745.00 | +7.8% | 2,809.00 | +5.3% |
| Other income | (18.00) | 31.00 | Turned loss | 33.00 | Turned loss |
| Total income | 2,941.00 | 2,776.00 | +5.9% | 2,842.00 | +3.5% |
| Profit before tax | 665.00 | 631.00 | +5.4% | 691.00 | −3.8% |
| Net profit for the period | 498.00 | 449.00 | +10.9% | 503.00 | −1.0% |
| EPS, basic (₹) | 14.71 | 13.27 | +10.9% | 14.88 | −1.1% |
| Net margin (%) | 16.8 | 16.4 | 17.9 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,433.00 | 2,143.00 | +13.5% | 2,377.00 | +2.4% |
| Other income | 15.00 | 76.00 | −80.3% | 3.00 | +400.0% |
| Total income | 2,448.00 | 2,219.00 | +10.3% | 2,380.00 | +2.9% |
| Profit before tax | 622.00 | 530.00 | +17.4% | 651.00 | −4.5% |
| Net profit for the period | 474.00 | 410.00 | +15.6% | 485.00 | −2.3% |
| EPS, basic (₹) | 14.00 | 12.12 | +15.5% | 14.33 | −2.3% |
| Net margin (%) | 19.5 | 19.1 | 20.4 |
Consolidated
- Filed with BSE
- 21 May 2025, 12:49 IST
- Board meeting
- 20 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 May 2025, 12:49 IST
- Board meeting
- 20 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE